Sustained Efficacy and Safety of Burosumab, an Anti-FGF23 Monoclonal Antibody, for 88 Weeks in Children and Early Adolescents with X-Linked Hypophosphatemia (XLH)
JOURNAL OF BONE AND MINERAL RESEARCH(2018)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要